Vincristine sulfate 1 mg inj
Products billed under this code include Vincristine Sulfate.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Vincristine Sulfate.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Vincristine Sulfate | Teva Parenteral Medicines, Inc. | 00703-4402-11 | 1 | $9.426 |
| Vincristine Sulfate | Teva Parenteral Medicines, Inc. | 00703-4412-11 | 2 | $18.852 |
| Vincristine Sulfate | Pfizer Inc | 61703-0309-06 | 1 | $9.426 |
| Vincristine Sulfate | Pfizer Inc | 61703-0309-16 | 2 | $18.852 |
| Vincristine Sulfate | Pfizer Inc | 61703-0309-25 | 2 | $18.852 |
| Vincristine Sulfate | Pfizer Inc | 61703-0309-26 | 1 | $9.426 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $9.426 | −$0.103 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted September 17, 2026 |
| 3Q26 | $9.529 | +$1.416 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted September 15, 2026 |
| 2Q26 | $8.113 | −$0.038 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted September 15, 2026 |
| 1Q26 | $8.151 | −$0.071 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted September 15, 2026 |
| 4Q25 | $8.222 | +$0.359 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted September 8, 2026 |
| 3Q25 | $7.863 | −$0.333 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted March 10, 2026 |
| 2Q25 | $8.196 | −$0.136 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted March 10, 2026 |
| 1Q25 | $8.332 | +$0.119 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted December 19, 2025 |
| 4Q24 | $8.213 | −$0.278 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted June 11, 2025 |
| 3Q24 | $8.491 | +$0.577 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted June 11, 2025 |
| 2Q24 | $7.914 | +$0.189 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted March 11, 2025 |
| 1Q24 | $7.725 | −$0.214 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted December 19, 2024 |
| 4Q23 | $7.939 | +$0.453 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted October 10, 2024 |
| 3Q23 | $7.486 | +$2.639 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted June 5, 2024 |
| 2Q23 | $4.847 | −$0.095 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted February 23, 2024 |
| 1Q23 | $4.942 | +$0.061 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted December 6, 2023 |
| 4Q22 | $4.881 | −$0.025 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted June 22, 2023 |
| 3Q22 | $4.906 | −$0.079 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted June 9, 2023 |
| 2Q22 | $4.985 | +$0.046 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted December 14, 2022 |
| 1Q22 | $4.939 | −$0.091 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted June 8, 2022 |
| 4Q21 | $5.03 | +$0.087 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted June 2, 2022 |
| 3Q21 | $4.943 | −$0.044 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted June 2, 2022 |
| 2Q21 | $4.987 | −$0.053 | 1 MG | Vincristine sulfate 1 mg inj | v1, posted March 1, 2022 |
| 1Q21 | $5.04 | – | 1 MG | Vincristine sulfate 1 mg inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.